Market Place
Sourcing Support
Actuate Receives EMA Orphan Status For Elraglusib In Cancer
07 Jan 2025 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Interim Data for Elraglusib
17 Dec 2024 //
GLOBENEWSWIRE
Actuate Therapeutics to be Added to Russell 2000® Index
26 Nov 2024 //
GLOBENEWSWIRE
Actuate Gets FDA Rare Pediatric Designation for Elraglusib
12 Nov 2024 //
GLOBENEWSWIRE
Actuate to Join Lantern’s Webinar on AI-Driven Drug Development
29 Oct 2024 //
GLOBENEWSWIRE
Actuate Reports Elraglusib Mechanism In Scientific Reports
23 Sep 2024 //
GLOBENEWSWIRE
Actuate Announces Elraglusib Data Presentation At AACR
16 Sep 2024 //
GLOBENEWSWIRE
Actuate Gets FDA Orphan Drug Designation For Elraglusib In Sarcomas
11 Sep 2024 //
GLOBENEWSWIRE
Actuate To Present At H.C. Wainwright Investment Conference
05 Sep 2024 //
GLOBENEWSWIRE
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
20 Aug 2024 //
GLOBENEWSWIRE
Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO
15 Aug 2024 //
FIERCE BIOTECH
Actuate Therapeutics Announces Closing of Initial Public Offering
14 Aug 2024 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Pricing of Initial Public Offering
12 Aug 2024 //
GLOBENEWSWIRE
Cancer-focused Actuate makes 2nd tweak to IPO plans in a week
24 Jul 2024 //
FIERCE BIOTECH
Actuate halves upcoming IPO to just $22M, scaling cancer drug
22 Jul 2024 //
FIERCE BIOTECH
Actuate unveils modest $50M IPO to fund cancer drug trials
17 Jul 2024 //
FIERCE BIOTECH
Clinical-stage cancer biotech Actuate latest to eye summer IPO
28 May 2024 //
FIERCE BIOTECH
Actuate Therapeutics Files Registration Statement for Initial Public Offering
28 May 2024 //
GLOBENEWSWIRE
Actuate Announces Poster Presentations at the 2024 AACR Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib
01 Aug 2023 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO
30 May 2023 //
GLOBENEWSWIRE
Actuate Announces Poster Presentations at the 2023 AACR Annual Meeting
10 Apr 2023 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Poster Presentations at 2023 AACR Annual Meeting
10 Apr 2023 //
GLOBENEWSWIRE
Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR
23 Mar 2023 //
GLOBENEWSWIRE
Drs. Roger B. Cohen, Lee M. Ellis & John L. Marshall Join Actuate’s Board
18 Oct 2022 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Poster Presentations at the 2022 AACR
28 Mar 2022 //
GLOBENEWSWIRE
Actuate Tx`s First Patient Enrolled in Phase 2 Trial of Elraglusib+Retifanlimab
01 Mar 2022 //
GLOBENEWSWIRE
Actuate Therapeutics Announces Primary Endpoin
28 Oct 2021 //
MEDINDIA
Actuate Therapeutics Announces FDA Fast Track Designation for 9-ING-41
05 Aug 2021 //
MEDINDIA
